Enzene Biosciences, a unit of India’s Alkem Laboratories, has unveiled plans to open a $50 million manufacturing facility near Princeton, New Jersey. The CDMO expects to hire as many as 300 new workers to support operations at the facility.
The plant will use continuous manufacturing technology and is expected to be fully operational by June 2024, according to a June 15 press release from Choose New Jersey.
The facility will be the first in the U.S. for the company, allowing Enzene to serve clients in North America with a streamlined supply chain and quicker turnaround times, the company said. The plant will support development and production of a “diverse range” of biologics, the company added.
“Enzene’s strategic expansion to New Jersey demonstrates Alkem Laboratories Ltd.’s commitment to investing in biologics CDMO,” Sandeep Singh, Alkem Labs' managing director, said in the release. “By establishing a presence in New Jersey, Enzene ensures its long-term viability and success as a trusted partner in delivering comprehensive CDMO services.”
Alkem was recently in the news when another of its subsidiaries, Ascend Labs, was forced to recall 10 lots of the anticoagulant dabigatran etexilate in capsule form. The recall was issued after higher than acceptable levels of the suspected carcinogen N-nitroso-dabigatran were found during routine testing.